Solid Biosciences (NASDAQ: SLDB) and Windtree Therapeutics (OTCMKTS:WINT) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk.
This is a breakdown of current ratings and recommmendations for Solid Biosciences and Windtree Therapeutics, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Insider and Institutional Ownership
56.0% of Solid Biosciences shares are owned by institutional investors. Comparatively, 0.0% of Windtree Therapeutics shares are owned by institutional investors. 0.8% of Windtree Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Solid Biosciences and Windtree Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Solid Biosciences and Windtree Therapeutics’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Solid Biosciences||N/A||N/A||-$52.11 million||($2.88)||-12.65|
|Windtree Therapeutics||$1.48 million||2.07||-$18.44 million||N/A||N/A|
Windtree Therapeutics has higher revenue and earnings than Solid Biosciences.
Solid Biosciences beats Windtree Therapeutics on 6 of the 9 factors compared between the two stocks.
Solid Biosciences Company Profile
Solid Biosciences Inc. engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation. In addition, it is developing soft wearable assistive devices that have functional and therapeutic benefits to DMD patients. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Windtree Therapeutics Company Profile
Windtree Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing novel surfactant therapies for respiratory diseases and other potential applications. Its proprietary technology platform includes a synthetic peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant and novel drug-delivery technologies being developed to enable noninvasive administration of aerosolized KL4 surfactant. The company's lead development program comprises AEROSURF, a drug/device product that is in Phase IIb clinical trial to treat respiratory distress syndrome in premature infants. It is also developing other aerosolized KL4 surfactant products. Windtree Therapeutics, Inc. has a strategic collaboration with Eleison Pharmaceuticals, Inc. for using its proprietary pulmonary aerosol delivery system to deliver inhaled lipid cisplatin in combination with KL4 surfactant. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was founded in 1992 and is headquartered in Warrington, Pennsylvania.
Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.